Intraday Trading Highlights
The pharmaceutical giant Lupin Ltd. recorded a significant intraday rally, with its stock price climbing 3.78% by the close of trading. The stock outperformed its sector peers by 2.38%, reflecting strong buying momentum throughout the session. Lupin’s shares traded above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum in the short to long term.
The stock’s intraday high of Rs 2,157.95 was achieved on the back of steady demand, despite the broader market’s subdued performance. Lupin’s 1-day gain of 3.60% starkly contrasts with the Sensex’s 0.44% decline, underscoring the stock’s relative strength in a challenging environment.
Market Context and Sector Comparison
On the same day, the Sensex opened 108.48 points lower and continued to slide, closing down 267.80 points at 85,063.34. The index remains 1.29% shy of its 52-week high of 86,159.02 but is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend despite short-term weakness.
Within the Pharmaceuticals & Biotechnology sector, Lupin Ltd. outperformed the sector average, which faced pressure amid the broader market downturn. The stock’s ability to buck the trend highlights its resilience and the strength of its trading action on the day.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Performance Trends Over Various Timeframes
Lupin Ltd.’s recent performance metrics reveal a pattern of relative strength compared to the Sensex. Over the past week, the stock gained 3.46%, outperforming the Sensex’s 0.46% rise. The 1-month performance shows a 2.64% increase for Lupin, while the Sensex declined by 0.76%. Over three months, Lupin surged 11.09%, significantly ahead of the Sensex’s 4.00% gain.
However, the 1-year performance indicates a decline of 8.65% for Lupin, contrasting with the Sensex’s 9.10% rise. Year-to-date, Lupin has gained 1.94%, slightly outperforming the Sensex’s marginal fall of 0.18%. Longer-term trends show Lupin’s 3-year return at 191.55%, well above the Sensex’s 42.01%, and a 5-year gain of 115.17% compared to the Sensex’s 76.57%. Over a decade, Lupin’s growth stands at 22.73%, trailing the Sensex’s 234.81%.
Mojo Score and Rating Update
Lupin Ltd. holds a Mojo Score of 74.0, reflecting a positive outlook based on a combination of financial health, price momentum, and quality metrics. The company’s Mojo Grade was upgraded from Hold to Buy on 12 Nov 2025, signalling improved confidence in its market positioning and performance. The Market Cap Grade remains at 1, indicating a large-cap status with stable market capitalisation.
Technical Indicators and Moving Averages
The stock’s trading above all major moving averages suggests a strong technical setup. The 5-day, 20-day, 50-day, 100-day, and 200-day moving averages all provide support levels below the current price, reinforcing the stock’s upward trajectory during the session. This technical strength is particularly notable given the broader market’s downward pressure on the Sensex.
Thinking about Lupin Ltd.? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this large-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
Summary of Trading Action
On 6 Jan 2026, Lupin Ltd. demonstrated a marked intraday rally, closing with a gain of 3.78% and touching an intraday peak of Rs 2,157.95. This performance was achieved despite a broadly negative market environment, with the Sensex falling 0.44%. The stock’s outperformance relative to both the Sensex and its sector peers highlights its strong demand and technical resilience.
The stock’s position above all key moving averages and its upgraded Mojo Grade to Buy further underscore the strength of its current trading action. Lupin’s relative gains over multiple timeframes, particularly in the short and medium term, reinforce its status as a notable performer within the Pharmaceuticals & Biotechnology sector.
Investors tracking Lupin Ltd. will note the stock’s ability to maintain momentum amid broader market pressures, supported by solid technical indicators and a favourable Mojo Score. The day’s trading session reflects a clear preference for Lupin shares, as evidenced by the intraday high and sustained buying interest.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
